ERBB2 and neoplasm: Chang et al. [37] showed that 3.75 μg of 89Zr-trastuzumab was administered via intravenous tail vein injection in HER2-positive MDA-MB-435-HER2 and negative MDA-MB-435-vector tumor xenograft models.